Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02031055
• Other study ID #: TPU-TAS-102-108
• Status: Completed
• Phase: Phase 1
• First received: December 18, 2013
• Last updated: June 15, 2017
• Start date: February 2014
• Est. completion date: June 17, 2015

Study information

• Verified date: June 2017
• Source: Taiho Oncology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate, in patients with advanced solid tumors, the mass balance of FTD and TPI after a single dose of TAS-102 with a light tracer dose of [14C]FTD or [14C]TPI.

Description:

This is a Phase 1, open-label study evaluating the mass balance of FTD and TPI after a single dose of TAS-102 with a light tracer dose of [14C]FTD or [14C]TPI. The study will be conducted in 2 parts: mass balance part and TAS-102 extension part. After completion of the mass balance part, patients will receive continued treatment with TAS-102 during the study extension part.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: June 17, 2015
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has advanced solid tumors (excluding previously treated breast cancer) for which no standard therapy exists

2. ECOG performance status of 0 or 1

3. Is able to take medications orally

4. Has adequate organ function (bone marrow, kidney and liver)

5. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.

Exclusion Criteria:

1. Has had certain other recent treatment e.g. anticancer therapy, received investigational agent, within the specified time frames prior to study drug administration

2. Certain serious illnesses or medical condition(s)

3. Has had either partial or total gastrectomy

4. Has a medical condition that jeopardizes or impairs ability to collect representative excreta

5. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies

6. Known sensitivity to TAS-102 or its components

7. Is a pregnant or lactating female

8. Refuses to use an adequate means of contraception (including male patients)

9. Is an occupationally exposed worker as defined by relevant ionizing radiation regulations

10. Has been exposed to 14C in the last 12 months

Related Conditions & MeSH terms

• Advanced Solid Tumors

Intervention

Drug:
• TAS-102 with a light tracer dose of [14C]FTD
A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 µg) of [14C]FTD administered as an oral solution on Day 1 (mass balance part)
• TAS-102 with a light tracer dose of [14C] TPI
A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 µg) of [14C]TPI administered as an oral solution on Day 1 (mass balance part)
• TAS-102 tablets
35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).

Locations

Country	Name	City	State
United States	University of Pittsbutgh Cancer Institute	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Taiho Oncology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary, fecal, and respiratory excretion of 14C from FTD and urinary and fecal excretion of 14C from TPI	Urine and feces samples will be collected at 24-hour intervals through 168 hours postdose. For [14C]FTD only, samples of CO2 will be trapped from expired air immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose.	Day 1 through day 8 (through 168 hours postdose)
Primary	PK parameters of total radioactivity (AUC0-inf, AUC0-last, Cmax, Tmax, and T1/2) in whole blood and plasma after a single dose of TAS-102		Blood will be collected immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours postdose
Primary	Metabolic profile of FTD and TPI in plasma, urine, and feces	Characterization of FTD and TPI metabolites	Blood will be collected immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours postdose. Urine and feces samples will be collected at 24-hour intervals through 168 hours postdose.
Primary	PK parameters of FTD, FTY, and TPI in plasma (Cmax, Tmax, AUC0-last, AUC0-inf, T1/2, CL/F, and Vd/F)	Cmax, Tmax, AUC0-last, AUC0-inf, and T1/2 will be calculated for each analyte, and CL/F and Vd/F will be calculated for FTD and TPI	Blood will be collected immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours postdose.
Secondary	Safety monitoring including adverse events, vital signs, and laboratory assessments	Standard safety monitoring and grading using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) will be used	Through 30 days following last administration of study medication or until initiation of new anticancer treatment, whichever comes first
Secondary	Tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST)		Every 8 weeks during the extension phase through Cycle 6 (through 24 weeks) and at least every 12 weeks thereafter, until treatment discontinuation (ie, due to disease progression, AEs, patient death, physician decision, pregnancy, or patient request)